| |
News |
Marketing authorisation of Enkorten in Bosnia and Herzegovina |
| Enkorten is registered in February 2010 in Bosnia and Herzegovina with a registration number 04-07.1-1655-1/09 issued from Drug Agency of Bosnia and Herzegovina. |
WCN 2009 |
| During the World Congress of Neurology (Bangkok, 24-30 October) Farmacija d.o.o. presented the results of phase III clinical study of Enkorten's efficacy in three different abstracts. Read more... |
Safety Profile |
| Safety profile of Enkorten was presented during the III Congress of neurology nurses and techicians in Opatija from 22 to 25 of April 2009. Read more... |
Clinical Phase III |
In December 2008 a complex statistical analysis of clinical phase III results was completed. Read more... |
Presentation of the clinical phase II |
Clinical phase II results of efficacy of Enkorten were presented during the 12 EFNS Congress in Spain in 2008.
Read more... |
| |
|
|
|
| News |
Clinical Phase III
In December 2008 a complex statistical analysis of the clinical phase III results was completed from the study entitled "Clinical investigation of the efficacy and safety of Enkorten use in the treatment of multiple sclerosis". Statistical analysis showed excellent efficacy of Enkorten as a drug that affects both the progression of disease and also a drug that can be used during relapses of disease. Safety profile of Enkorten has confirmed its uniqueness, so that during the clinical phase III there was no report of any serious adverse events, confirming the previous results.
|
|
|
|
|
